Måndag 16 November | 18:10:14 Europe / Stockholm
Est. tid*
2027-02-18 07:30 Bokslutskommuniké 2026
2026-11-03 - Kvartalsrapport 2026-Q3
2026-08-20 - Kvartalsrapport 2026-Q2
2026-06-12 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2026-06-11 - Årsstämma
2026-05-27 - Kvartalsrapport 2026-Q1
2026-02-18 - Bokslutskommuniké 2025
2025-11-27 - Extra Bolagsstämma 2025
2025-10-30 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-28 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2025-05-27 - Årsstämma
2025-05-27 - Kvartalsrapport 2025-Q1
2025-02-18 - Bokslutskommuniké 2024
2024-12-13 - Extra Bolagsstämma 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-31 - Kvartalsrapport 2024-Q1
2024-05-24 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2024-05-23 - Årsstämma
2024-02-23 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-08-04 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2023-05-25 - Årsstämma
2023-05-05 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2023-01-12 - Extra Bolagsstämma 2022
2022-11-04 - Kvartalsrapport 2022-Q3
2022-08-05 - Kvartalsrapport 2022-Q2
2022-05-30 - Kvartalsrapport 2022-Q1
2022-05-23 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2022-05-20 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-24 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2021-05-21 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-12 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-14 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2020-05-13 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-11 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-11-08 - Extra Bolagsstämma 2019
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-13 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2019-05-10 - Årsstämma
2019-04-24 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-05-16 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2018-05-15 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-13 - Bokslutskommuniké 2017
2017-11-03 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning SYNACT 0.00 SEK
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-02-09 - Bokslutskommuniké 2016
2016-11-04 - Kvartalsrapport 2016-Q3
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
SynAct Pharma är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för inflammatoriska sjukdomar. Bolaget forskar på nya terapier som kan minska inflammation och förbättra patientresultat. Verksamheten är global med en huvudsaklig närvaro i Europa och Nordamerika. SynAct Pharma grundades år 2012 och har sitt huvudkontor i Lund.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

SynAct Pharma publishes Q3 2026 interim results

2026-11-03 07:30:00

SynAct Pharma AB (publ) (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as “pro-resolution”, today publishes its interim report for the third quarter 2026.

“SynAct Pharma continued to progress in the third quarter of 2026, both clinically, with our novel pro-resolution therapeutic approach, and financially. Further analysis of data from the ADVANCE study with resomelagon in rheumatoid arthritis provides a clearer basis for designing our Phase 3 trial. We expect feedback from the U.S. Food and Drug Administration by end of year or early 2027. With financial flexibility and funding in place beyond multiple potential value creating milestones, we are well positioned to plot the most suitable route forward for resomelagon while, in parallel, continuing to advance our active partnering discussions,” said Jeppe Øvlesen, Chief Executive Officer of SynAct Pharma.

Third quarter 2026 (July – September)

Year ago figures (in brackets)

  • The Group’s net sales amounted to SEK 0 (0).
  • Operating expenses amounted to SEK 30,087 (35,377) thousand, a decrease of 15.0%.
  • The Group’s loss after tax amounted to SEK 32,177 (35,690) thousand.
  • The Group’s earnings per share before and after dilution amounted to -0.57 (-0.67) SEK.
  • Cash flow from operating activities amounted to SEK -18,714 (-25,751) thousand.
  • Cash flow from financing activities amounted to SEK 46,241 (34,934) thousand.
  • Cash flow for the period amounted to SEK 27,370 (9,183) thousand.
  • Cash and cash equivalents at the end of the period amounted to SEK 42,364 (77,939) thousand, providing cash runway into the fourth quarter of 2027 and beyond multiple potential value creating milestones.

First nine months 2026 (January – September) 

  • The Group’s net sales amounted to SEK 0 (0).
  • Operating expenses amounted to SEK 85,201 (93,820) thousand.
  • The Group’s loss after tax amounted to SEK 79,696 (87,897) thousand.
  • The Group’s earnings per share before and after dilution amounted to -1.44 (-1.75) SEK.
  • Cash flow from operating activities amounted to SEK -86,206 (-73,365) thousand.
  • Cash flow from financing activities amounted to SEK 88,466 (90,605) thousand.
  • Cash flow for the period amounted to SEK -11,791 (17,241) thousand.
     

Significant events during the third quarter

Significant events after the end of the period

The full report is attached as PDF and is available on the company’s website: https://www.synactpharma.com/en/investors/financial-reports/

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

Investors and Media
Mary-Ann Chang, Cohesion Bureau
E-mail: synactpharma@cohesionbureau.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical-stage biotechnology company pioneering pro-resolution therapies for inflammation through selective activation of the melanocortin system. Its lead asset, resomelagon (AP1189), is a once-daily oral, first-in-class biased agonist of the MC1 and MC3 melanocortin receptors, that has completed Phase 2b development in rheumatoid arthritis, and is in Phase 2 development as host-directed therapy to treat inflammation caused by infections, including respiratory viral infection and dengue. Behind resomelagon, SynAct is building a broad portfolio of oral small molecule and injectable peptide melanocortin agonists designed to induce anti-inflammatory pro-resolution activity, helping patients restore immune balance. For more information, please visit www.synactpharma.com.